Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 3 for:    DS6051
Previous Study | Return to List | Next Study

A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02279433
Recruitment Status : Completed
First Posted : October 31, 2014
Last Update Posted : September 22, 2020
Sponsor:
Information provided by (Responsible Party):
AnHeart Therapeutics Inc.

Tracking Information
First Submitted Date  ICMJE October 15, 2014
First Posted Date  ICMJE October 31, 2014
Last Update Posted Date September 22, 2020
Study Start Date  ICMJE September 2014
Actual Primary Completion Date March 2019   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: September 18, 2020)
  • Part 1: Number of participants with dose-limiting toxicities [ Time Frame: within 21 days following the first dose of treatment ]
  • Tumor response [ Time Frame: up to 2 years ]
    Tumor response will be assessed using Response Evaluation Criteria In Solid Tumors (RECIST) 1.1.
Original Primary Outcome Measures  ICMJE
 (submitted: October 28, 2014)
  • Part 1: Number of participants with dose-limiting toxicities [ Time Frame: 21 days following the first dose of treatment ]
  • Part 2: Tumor response [ Time Frame: Every 9 weeks from enrollment up to 2 years ]
    Tumor response will be assessed using Response Evaluation Criteria In Solid Tumors (RECIST) 1.1.
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: September 18, 2020)
  • Maximum concentration (Cmax) for DS-6051a [ Time Frame: At Days 1 and 15 of Cycle 1 (21 days) ]
  • Time to maximum concentration (Tmax) for DS-6051a [ Time Frame: At Days 1 and 15 of Cycle 1 (21 days) ]
  • Area under the concentration-time curve from time zero to t (AUC0-t) for DS-6051a [ Time Frame: At Days 1 and 15 of Cycle 1 (21 days) ]
  • Change from baseline in QTc interval [ Time Frame: within 2 years ]
    ECGs performed to assess QTc interval (ms) at baseline and on study treatment and at the end of treatment visit.
Original Secondary Outcome Measures  ICMJE
 (submitted: October 28, 2014)
  • Composite of plasma exposure parameters of DS-6051a [ Time Frame: At Days 1 and 15 of Cycle 1 ]
    Maximum concentration (Cmax), time to maximum plasma concentration (Tmax), and area under the concentration-time curve from time zero to t (AUC0-t) for DS-6051a (a free base form of DS-6051b) will be assessed on Days 1 and 15 of Cycle 1.
  • Changes in QTc interval [ Time Frame: At screening, Days 1, 2, 8, and 15 of Cycle 1, Days 1, 8, and 15 of Cycle 2, Days 1 and 15 of Cycle 3, Day 1 of Cycle 4 and thereafter, and within 2 days after the last dose of treatment ]
    ECGs performed to assess QTc interval (ms) at baseline and on study treatment and at the end of treatment visit.
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b
Official Title  ICMJE A Phase 1/1B Multi-Center, Non Randomized, Open-Label, Multiple Dose First-In-Human Study Of DS-6051b, An Oral ROS1 And NTRK Inhibitor, In Subjects With Metastatic and/or Unresectable Solid Tumors
Brief Summary DS-6051b is an orally administered inhibitor of the tyrosine kinases (ROS1) and neurotropic tyrosine kinase receptors (NTRK). This phase 1 first-in-human study evaluates safety and tolerability of DS-6051b in cancer subjects and identify a recommended phase 2 dose (RP2D). In addition, this study will also assess the pharmacokinetic (PK)/pharmacodynamic (PD) profiles and preliminary efficacy of DS-6051b.
Detailed Description

The Dose Escalation part (Part 1) of this study will evaluate safety and tolerability, and determine the tentative RP2D. Plasma exposure of DS-6051a and the exposure - QT interval prolongation relationship will also be assessed. Approximately 30 subjects with advanced solid tumors harboring ROS1 or NTRK1, NTRK2, or NTRK3 rearrangement, neuroendocrine carcinoma, or with advanced solid tumors and tumor-induced pain will be enrolled.

The Food Effect (FE) part of this study is to determine the effect of food on the PK of DS-6051a following administration of a single oral dose of DS-6051b. The safety and tolerability of DS-6051b administered with or without food will also be assessed.

After the safety profile of DS-6051b is adequately evaluated, the Dose Expansion part (Part 2) will be initiated to further assess the safety and tolerability, and preliminarily evaluate the efficacy of DS-6051b at the tentative RP2D. Approximately 40 cancer subjects carrying a ROS1 or NTRK1, NTRK2, or NTRK3 rearrangement will be enrolled.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Solid Tumors
Intervention  ICMJE Drug: DS6051b
DS-6051b 50 mg and 200 mg capsules for oral administration
Other Names:
  • Investigational product
  • DS-6051a (a free base of 6051b)
Study Arms  ICMJE Experimental: DS-6051b
DS-6051b is orally administered as 50 mg and 200 mg capsules once daily on Days 1 to 21 of a 21-day cycle. Dose escalation in Part 1 will continue until tentative Recommended Part 2 Dose (RP2D) is determined. In Part 2 participants will receive the RP2D.
Intervention: Drug: DS6051b
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: September 18, 2020)
46
Original Estimated Enrollment  ICMJE
 (submitted: October 28, 2014)
70
Actual Study Completion Date  ICMJE March 2019
Actual Primary Completion Date March 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Histologically or cytologically confirmed diagnosis of advanced solid tumors that have relapsed from or are refractory to standard treatment or for which no standard treatment is available
  2. Part 1 Dose Escalation subjects must meet 1 of the following criteria:

    • Solid tumors with documented ROS1, NTRK1, NTRK2, or NTRK3 rearrangement
    • Neuroendocrine tumors
    • Solid tumors with tumor-induced pain
  3. Part 2 Dose Expansion subjects must meet 1 of the following criteria:

    • NSCLC with documented ROS1, NTRK1, NTRK2, or NTRK3 rearrangement
    • k-RAS wild-type CRC with documented NTRK1, NTRK2, or NTRK3 rearrangement
    • Other solid tumors with documented ROS1, NTRK1, NTRK2, or NTRK3 rearrangement
    • Pulmonary LCNEC;
  4. Male or female ≥18 years of age
  5. Eastern Cooperative Oncology Group performance status 0 to 1
  6. Adequate organ function
  7. Adequate blood clotting function
  8. Women of childbearing potential must have a negative pregnancy test
  9. Willingness to provide archival tumor samples
  10. Other inclusion criteria may apply

Exclusion Criteria:

  1. Hematological malignancies
  2. Known positive HIV infection, or active hepatitis B or C infection
  3. Comorbidity that would interfere with therapy
  4. Receipt of an allogeneic bone marrow or allogeneic stem cell transplant
  5. Concomitant medical condition that would increase the risk of toxicity, in the opinion of the Investigator or Sponsor
  6. History of myocardial infarction and unstable angina within 6 months before study drug treatment; symptomatic congestive heart failure (Congestive Heart Failure New York Heart Association Class III or IV); congenital long QT syndrome; or ventricular arrhythmias defined as grade ≥2 according to NCI CTCAE, v4
  7. Clinically active primary central nervous system tumors or brain metastases with the exception of subjects with glioblastoma multiform that carry ROS1 rearrangement
  8. Unresolved toxicities from previous anticancer therapy
  9. Systemic treatment with anticancer therapy within 3 weeks before study drug treatment
  10. Therapeutic radiation therapy or major surgery within 4 weeks before study drug treatment or palliative radiation therapy within 2 weeks before study drug treatment
  11. Participation in a therapeutic clinical study within 3 weeks for biological treatments, and within 2 weeks or 5 half-lives, whichever is longer, for small molecule agents, before study drug treatment
  12. Concomitant treatment with strong inhibitors or inducers of CYP3A4 and P-glycoprotein
  13. Clinically significant malabsorption syndrome or other gastrointestinal disease that would impact drug absorption
  14. QTcF values higher than 450 ms at screening
  15. Breastfeeding
  16. Other exclusion criteria may apply
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02279433
Other Study ID Numbers  ICMJE DS6051-A-U101
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party AnHeart Therapeutics Inc.
Study Sponsor  ICMJE AnHeart Therapeutics Inc.
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Study Director Oncology AnHeart Therapeutics Inc.
PRS Account AnHeart Therapeutics Inc.
Verification Date July 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP